Pérez-Martínez P, Adarraga-Cansino M D, Fernández de la Puebla R A, Blanco-Molina A, Delgado-Lista J, Marín C, Ordovás J M, López-Miranda J, Pérez-Jiménez F
Lipids and Atherosclerosis Research Unit, Hospital Universitario Reina Sofia, CIBER, Fisiopatologia, Obesidad y Nutricion, Avda. Menendez Pidal, s/n. 14004 Cordoba, Spain.
Br J Nutr. 2008 Apr;99(4):699-702. doi: 10.1017/S0007114507831710. Epub 2007 Oct 1.
The objective of the study was to determine whether Plasminogen Activator Inhibitor Type 1 (PAI-1) -675 4G/5G polymorphism is associated with the response of functional plasma PAI-1 concentrations to changes in the amount and quality of dietary fat in healthy subjects. PAI-1 is the major inhibitor of fibrinolysis, and a lower level of fibrinolytic activity could be implicated in an increased risk of IHD. Fifty-nine healthy Spanish volunteers (ten 4G/4G homozygotes, twenty-eight heterozygotes 4G/5G and twenty-one 5G/5G homozygotes) consumed three diets for periods of 4 weeks each: a SFA-rich diet (38 % fat, 20 % SFA), followed by a carbohydrate-rich diet (30 % fat, 55 % carbohydrate) and a MUFA-rich diet (38 % fat, 22 % MUFA) according to a randomized crossover design. At the end of each dietary period plasma lipid and functional plasma PAI-1 concentrations were determined. Subjects carrying the 4G allele (4G/4G and 4G/5G) showed a significant decrease in PAI-1 concentrations after the MUFA diet, compared with the SFA-rich and carbohydrate-rich diets (genotype x diet interaction: P = 0.028). 5G/5G homozygotes had the lowest plasma PAI-1 concentrations compared with 4G/4G and 4G/5G subjects (genotype: P = 0.002), without any changes as a result of the amount and the quality of the dietary fat. In summary, no differences in plasma PAI-1 concentration response were found after changes in dietary fat intake in 5G/5G homozygotes, although these subjects displayed the lowest concentrations of PAI-1. On the other hand, carriers of the 4G allele are more likely to hyper-respond to the presence of MUFA in the diet because of a greater decrease in PAI-1 concentrations.
本研究的目的是确定纤溶酶原激活物抑制剂1型（PAI-1）-675 4G/5G多态性是否与健康受试者功能性血浆PAI-1浓度对膳食脂肪数量和质量变化的反应有关。PAI-1是纤维蛋白溶解的主要抑制剂，较低水平的纤维蛋白溶解活性可能与缺血性心脏病风险增加有关。59名健康的西班牙志愿者（10名4G/4G纯合子、28名4G/5G杂合子和21名5G/5G纯合子）按照随机交叉设计，每种饮食各食用4周：富含饱和脂肪酸的饮食（38%脂肪，20%饱和脂肪酸），随后是富含碳水化合物的饮食（30%脂肪，55%碳水化合物）和富含单不饱和脂肪酸的饮食（38%脂肪，22%单不饱和脂肪酸）。在每个饮食阶段结束时，测定血浆脂质和功能性血浆PAI-1浓度。与富含饱和脂肪酸和富含碳水化合物的饮食相比，携带4G等位基因（4G/4G和4G/5G）的受试者在食用富含单不饱和脂肪酸的饮食后，PAI-1浓度显著降低（基因型×饮食相互作用：P = 0.028）。与4G/4G和4G/5G受试者相比，5G/5G纯合子的血浆PAI-1浓度最低（基因型：P = 0.002），且不因膳食脂肪的数量和质量而发生任何变化。总之，5G/5G纯合子在膳食脂肪摄入改变后，血浆PAI-1浓度反应未发现差异，尽管这些受试者的PAI-1浓度最低。另一方面，由于PAI-1浓度下降幅度更大，4G等位基因携带者对饮食中存在的单不饱和脂肪酸更易产生高反应。
